With siRNA-based drugs becoming established as a therapeutic modality, large companies are engaging in the field through deals and acquisitions, cardiovascular metabolic diseases among their targets.

Today, pancreatic cancer ranks second after the cardiovascular system among causes of death. The which is an aggressive type progressing without giving too many symptoms. In addition, factors such as difficulty in early diagnosis, rapid metastasis and non-response to traditional treatments cause a low survival rate this cancer. Therefore, studies are carried out develop alternative diagnosis tr...

Background: It is thought that a limited number of aberrant cancer stem cells (CSCs), which encourage carcinogenesis, tumor metastasis, and treatment resistance, are the cause pancreatic cancer, disease with high mortality rate. Increasing evidence shows CSCs use immunosuppressive properties to avoid immune system identification. In Pancreatic therapeutic consequences relationship between expre...

objective(s): the oct4b1, as one of oct4 variants, is expressed in cancer cell lines and tissues more than other variants and plays an important role in apoptosis and stress (heat shock protein) pathways. the present study was designed to determine the effects of oct4b1 silencing on expressional profile of hsp40 gene family expression in three different human tumor cell lines. materials and met...

Engineered peptide based biocompatible, siRNA transporter can transfect primary and TNBC cells with efficient long-term gene silencing. Nanocomplex silencing Notch1 exhibits synergistic interaction metformin amplifies anticancer therapy.